FDA approves J&J’s Icotyde for plaque psoriasis

Johnson & Johnson has secured a notable US regulatory win in immunodermatology, with the FDA approving Icotyde (icotrokinra) on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and adolescents age 12 and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. According to the company, Icotyde is the first and only approved oral peptide that selectively blocks the IL-23 receptor, giving J&J a new entrant in a crowded psoriasis market that has been dominated by injectable biologics and, more recently, oral small molecules. (investor.jnj.com)

The approval didn’t come out of nowhere. J&J had signaled the filing in mid-2025, when it said it was seeking the first FDA approval for icotrokinra based on the Phase 3 ICONIC program. That program was designed to support a shift in the treatment paradigm for patients who need more than topicals but may hesitate to move to injectable biologics. In that sense, Icotyde sits at an important commercial and clinical intersection: an oral therapy aiming for efficacy closer to biologics, while preserving the convenience many patients prefer in a pill. (investor.jnj.com)

Key data from the development program help explain the FDA’s decision. In the Phase 3 ICONIC-LEAD trial, once-daily icotrokinra met co-primary endpoints at Week 16, with about 65% of treated patients achieving an Investigator’s Global Assessment score of 0/1 and 50% achieving PASI 90, compared with 8% and 4% for placebo, respectively. In the Phase 3 ICONIC-ADVANCE 1 and 2 studies, icotrokinra was superior to placebo on the primary endpoints at Week 16 and also outperformed deucravacitinib at Week 24, according to J&J and a PubMed-indexed report of the trials. Across the ADVANCE studies, adverse-event rates through Week 16 were broadly comparable between icotrokinra and placebo, with nasopharyngitis and upper respiratory tract infection among the most common events reported. (investor.jnj.com)

J&J has continued to build the launch narrative since approval. On March 28, 2026, the company released one-year data from ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD, saying the results showed durable skin clearance and a favorable safety profile through 52 weeks. In that same announcement, investigator Jennifer Soung, MD, described the therapy as giving patients age 12 and older access to a novel once-daily option with sustained clearance. Trade coverage in Dermatology Times likewise framed the approval as a first-in-class oral IL-23 receptor blocker and one of the field’s notable recent developments. (investor.jnj.com)

There’s also a broader competitive backdrop. Takeda has been presenting Phase 3 data for zasocitinib in plaque psoriasis at AAD 2026, underscoring how quickly the advanced oral psoriasis category is evolving. That means Icotyde’s approval is both a regulatory milestone and an opening move in what may become a more intense race among oral immunology agents promising stronger efficacy than earlier-generation pills. For market watchers, the differentiation story will likely center on efficacy durability, safety, formulary positioning, and how readily dermatologists use the drug before injectable biologics. (dermatologytimes.com)

Why it matters: For veterinary professionals, this is relevant less because of direct clinical crossover and more because it reflects the direction of inflammatory disease innovation. Companion-animal medicine has seen rising interest in targeted immunomodulation, especially in dermatology, allergy, and chronic inflammatory conditions. A successful oral IL-23 receptor program in humans may influence R&D thinking across species, especially if it reinforces the idea that peptide-based, pathway-specific therapies can combine convenience with high efficacy. It may also affect conversations with pet parents, who often bring expectations from human medicine into veterinary visits, particularly around chronic skin disease management, long-term safety, and preference for oral over injectable treatment. Those expectation shifts don’t create veterinary indications, but they do shape demand, adherence discussions, and perceptions of what “modern” care should look like. (investor.jnj.com)

What to watch: Next, watch for formal label dissemination and payer decisions, post-launch prescription trends, publication of additional long-term and subgroup analyses, and whether competitors such as Takeda can narrow the differentiation gap in oral psoriasis therapy. For veterinary industry readers, the bigger question is whether this approval remains a human-only market event or becomes another proof point that targeted oral immunology is the platform to watch across chronic inflammatory disease. (drugs.com)